Fig. 2From: The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysisEvidence summary – SGLT2 inhibitors compared to control for cardio-renal risk reductionBack to article page